QUOIN PHARMACEUT.ADR5000
Research QUOIN PHARMACEUT.ADR5000 (2EB0) on Bullrun: market cap EUR 8.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2EB0
- ExchangeF
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 8.15M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 5.00M
- Free cash flow-USD 4.87M
Valuation Snapshot
latest market cap is EUR 8.15M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 15.80M | -USD 13.54M | n/a | -21.23 | USD 3.82M | n/a | USD 13.12M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 8.15M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About QUOIN PHARMACEUT.ADR5000
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is QUOIN PHARMACEUT.ADR5000's market cap?
QUOIN PHARMACEUT.ADR5000's market capitalization is EUR 8.15M.
What does QUOIN PHARMACEUT.ADR5000 do?
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.